Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 29;5(3):FSO372.
doi: 10.4155/fsoa-2018-0115. eCollection 2019 Mar.

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy

Ali Alqahtani  1   1 , Khalil Choucair  2   2 , Mushtaq Ashraf  2   2 , Danae M Hammouda  2   2 , Abduraham Alloghbi  1   1 , Talal Khan  2   2 , Neil Senzer  2   2 , John Nemunaitis  2   3   2   3
Affiliations
Review

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy

Ali Alqahtani et al. Future Sci OA. .

Abstract

Histone lysine acetylation is critical in regulating transcription. Dysregulation of this process results in aberrant gene expression in various diseases, including cancer. The bromodomain, present in several proteins, recognizes promotor lysine acetylation and recruits other transcription factors. The bromodomain extra-terminal (BET) family of proteins consists of four conserved mammalian members that regulate transcription of oncogenes such as MYC and the NUT fusion oncoprotein. Targeting the acetyl-lysine-binding property of BET proteins is a potential therapeutic approach of cancer. Consequently, following the demonstration that thienotriazolodiazepine small molecules effectively inhibit BET, clinical trials were initiated. We thus discuss the mechanisms of action of various BET inhibitors and the prospects for their clinical use as cancer therapeutics.

Keywords: BET inhibitors; BET protein; cancer; clinical trials; combination therapy; hematological malignancies; solid tumors; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Biology of bromodomain and extra-terminal inhibitors and their role in cancer therapy.
BET protein binds to acetylated histones and recruits, via its BRD4 domain, PTEF-b to sites of active transcription of growth-promoting genes such as MYC and NUT. In addition, the ET domain of BRD4 independently recruits transcriptional activators such as NSD3, JMJD6 and CHD4 to further increase rates of transcription. BET inhibitors block the initial binding of BET proteins to acetylated histones, and thus halts the transcriptional cascade of oncogenes. BET: Bromodomain and extra-terminal; PTEF-b: Positive transcriptional elongation factor complex.
See this image and copyright information in PMC

References

    1. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–840. - PubMed

    2. • Comprehensive review of the role of lysine acetylation in various diseases.

    1. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays. 1998;20(8):615–626. - PubMed
    1. Lombardi PM, Cole KE, Dowling DP, Christianson DW. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol. 2011;21(6):735–743. - PMC - PubMed
    1. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 2014;13(5):337–356. - PubMed
    1. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol. Oncol. 2012;6(6):579–589. - PMC - PubMed

LinkOut - more resources